Search research articles
Contact Us
Filters
Showing results (21-30 of 46) with videos related to
Page
of 5
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
February 1, 2006
Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America
George H Talbot, John Bradley, John E Edwards, et al.
The Journal of Antimicrobial Chemotherapy
|
December 1, 2010
CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections
G Ralph Corey, Mark H Wilcox, George H Talbot, et al.
The Journal of Antimicrobial Chemotherapy
|
December 1, 2010
CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections
Mark H Wilcox, G Ralph Corey, George H Talbot, et al.
The New England Journal of Medicine
|
June 5, 2014
Once-weekly dalbavancin versus daily conventional therapy for skin infection
Helen W Boucher, Mark Wilcox, George H Talbot, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
June 30, 2012
Progress on developing endpoints for registrational clinical trials of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections: update from the Biomarkers Consortium of the Foundation for the National Institutes of Health
George H Talbot, John H Powers, Thomas R Fleming, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
November 20, 2008
Position paper: recommended design features of future clinical trials of antibacterial agents for community-acquired pneumonia
Brad Spellberg, George H Talbot, Eric P Brass, et al.
Health and Quality of Life Outcomes
|
May 5, 2019
Clostridium difficile Infection-Daily Symptoms (CDI-DaySyms™) questionnaire: psychometric characteristics and responder thresholds
George H Talbot, Leah Kleinman, Evan Davies, et al.
Antimicrobial Agents and Chemotherapy
|
May 11, 2016
In Vitro Activity of Lefamulin Tested against Streptococcus pneumoniae with Defined Serotypes, Including Multidrug-Resistant Isolates Causing Lower Respiratory Tract Infections in the United States
Rodrigo E Mendes, David J Farrell, Robert K Flamm, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
June 27, 2009
Antimicrobial agents for complicated skin and skin-structure infections: justification of noninferiority margins in the absence of placebo-controlled trials
Brad Spellberg, George H Talbot, Helen W Boucher, et al.
The Pediatric Infectious Disease Journal
|
October 24, 2002
Safety and efficacy of quinupristin/dalfopristin for treatment of invasive Gram-positive infections in pediatric patients
Ann M Loeffler, Richard H Drew, John R Perfect, et al.
Page
of 5
Search research articles
Search
Showing results (21-30 of 46) with videos related to
Sort By:
Page
of 5
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
February 1, 2006
Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America
George H Talbot, John Bradley, John E Edwards, et al.
The Journal of Antimicrobial Chemotherapy
|
December 1, 2010
CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections
G Ralph Corey, Mark H Wilcox, George H Talbot, et al.
The Journal of Antimicrobial Chemotherapy
|
December 1, 2010
CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections
Mark H Wilcox, G Ralph Corey, George H Talbot, et al.
The New England Journal of Medicine
|
June 5, 2014
Once-weekly dalbavancin versus daily conventional therapy for skin infection
Helen W Boucher, Mark Wilcox, George H Talbot, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
June 30, 2012
Progress on developing endpoints for registrational clinical trials of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections: update from the Biomarkers Consortium of the Foundation for the National Institutes of Health
George H Talbot, John H Powers, Thomas R Fleming, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
November 20, 2008
Position paper: recommended design features of future clinical trials of antibacterial agents for community-acquired pneumonia
Brad Spellberg, George H Talbot, Eric P Brass, et al.
Health and Quality of Life Outcomes
|
May 5, 2019
Clostridium difficile Infection-Daily Symptoms (CDI-DaySyms™) questionnaire: psychometric characteristics and responder thresholds
George H Talbot, Leah Kleinman, Evan Davies, et al.
Antimicrobial Agents and Chemotherapy
|
May 11, 2016
In Vitro Activity of Lefamulin Tested against Streptococcus pneumoniae with Defined Serotypes, Including Multidrug-Resistant Isolates Causing Lower Respiratory Tract Infections in the United States
Rodrigo E Mendes, David J Farrell, Robert K Flamm, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
June 27, 2009
Antimicrobial agents for complicated skin and skin-structure infections: justification of noninferiority margins in the absence of placebo-controlled trials
Brad Spellberg, George H Talbot, Helen W Boucher, et al.
The Pediatric Infectious Disease Journal
|
October 24, 2002
Safety and efficacy of quinupristin/dalfopristin for treatment of invasive Gram-positive infections in pediatric patients
Ann M Loeffler, Richard H Drew, John R Perfect, et al.
Page
of 5